Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an announcement.
Clarity Pharmaceuticals has signed a large-scale manufacturing supply agreement with Theragenics for copper-64 production at Theragenics’ high-capacity cyclotron facility near Atlanta, Georgia, positioning the company for commercial rollout of its prostate cancer imaging agent 64Cu-SAR-bisPSMA, subject to successful Phase III trials and regulatory approvals. The deal expands Clarity’s U.S. isotope supply network alongside existing partners SpectronRx and Nusano, underpinning a scalable, nationwide distribution model that leverages copper-64’s longer half-life to reduce waste and logistics constraints, and potentially strengthen Clarity’s competitive position in next-generation radiopharmaceutical diagnostics.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is an Australia-based clinical-stage radiopharmaceutical company focused on developing targeted copper theranostics for the treatment and diagnosis of serious cancers. Its products are built on a proprietary SAR Technology Platform, with a key focus on prostate cancer imaging agents such as 64Cu-SAR-bisPSMA aimed at improving radiodiagnostics and patient outcomes.
Average Trading Volume: 2,130,362
Technical Sentiment Signal: Sell
Current Market Cap: A$1.17B
See more insights into CU6 stock on TipRanks’ Stock Analysis page.